![](https://4982731c.rocketcdn.me/wp-content/uploads/2024/01/Jerry-Circle-1-150x150.png)
Jerry Chapman
Senior GMP Quality Expert
Areas examined in this report:
- Pharma compliance issue trends
- The role of EIRs
- When FDA inspections are classified as OAI
- Timing of surveillance inspections following pre-approval inspections
- A case study in contamination failures that led to patient deaths
- The series of events that resulted in a company coming under a consent decree